STCube, Inc. (KOSDAQ:052020)

South Korea flag South Korea · Delayed Price · Currency is KRW
14,150
-1,550 (-9.87%)
Mar 20, 2026, 3:30 PM KST
Market Cap961.26B +88.6%
Revenue (ttm)6.81B -31.5%
Net Income-20.15B
EPS-310.73
Shares Out67.93M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,002,532
Average Volume847,966
Open15,700
Previous Close15,700
Day's Range14,140 - 16,160
52-Week Range5,500 - 19,250
Beta-0.01
RSI59.91
Earnings DateMar 24, 2026

About STCube

STCube, Inc., a biopharmaceutical company, develops medicines in South Korea. The company develops anti-cancer immunotherapeutic drugs and anti-viral drugs. It offers platform technologies, which include In vivo RNAi ICP target discovery platform for exploring material ICP target; glycosylation-specific antibody development platform for development of antibodies that mask glycosylation sites on target proteins; and ICP functional assay platform for development of various in vivo/in vitro analytical/experimental methods. The company’s product pi... [Read more]

Industry Technology Distributors
Sector Technology
Founded 1989
Employees 13
Stock Exchange KOSDAQ
Ticker Symbol 052020
Full Company Profile

Financial Performance

In 2024, STCube's revenue was 11.30 billion, an increase of 93.88% compared to the previous year's 5.83 billion. Losses were -21.44 billion, -12.52% less than in 2023.

Financial Statements